Stellar Biotechnologies Announces Approval of NASDAQ Uplisting
Stellar to Trade on NASDAQ Under Symbol "SBOT" and to Ring Closing Bell on November 5, 2015
(firmenpresse) - PORT HUENEME, CA -- (Marketwired) -- 11/03/15 -- (OTCQB: SBOTF) (TSX VENTURE: KLH)the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), today announced that the Company has received approval for its common shares to begin trading on The NASDAQ Capital Market ("Nasdaq").
Stellar''s common shares will begin trading on Nasdaq under the symbol "SBOT" at market open on Thursday, November 5, 2015. In addition, Nasdaq has invited Stellar to ring the Nasdaq Closing Bell that day.
"This is a significant milestone for Stellar and an important step in our corporate growth," said Frank Oakes, President, Chief Executive Officer and Chairman. "We anticipate that the listing of our shares on NASDAQ will raise our visibility within the investment community and with institutional investors, and will offer our shareholders an opportunity for increased liquidity. This approval comes at an important time for Stellar, as evidenced by our recently announced plan to expand manufacturing capacity to meet growing demand for KLH protein in immunotherapy. We look forward to sharing our future achievements with investors, customers, and collaborators."
In celebration of the Company''s listing on the exchange, CEO Frank Oakes and members of Stellar''s management team will participate in the Nasdaq closing ceremony on Thursday, November 5, 2015 at 4:00 PM ET (1:00 PM PT) at the Nasdaq MarketSite in New York City. The event will be broadcast live via Nasdaq''s livestream portal at .
Thursday, November 5, 2015 (at) 4:00 PM ET (1:00 PM PT)
Link to Live Webcast:
Archive available after November 5 at:
Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer''s and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.
Visit and the KLH knowledge base .
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; governmental regulations and the ability or failure to comply with governmental regulations; the timing of anticipated results; and other factors referenced in the Company''s filings with securities regulators. For a discussion of further risks and uncertainties related to the Company''s business, please refer to the Company''s public company reports filed with the TSX Venture Exchange and the U.S. Securities and Exchange Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the information contained in this press release.
Mark A. McPartland
Vice President of Corporate Development and Communications
Phone: +1 (805) 488-2800 ext. 103
Joseph Green
The Ruth Group
Phone: +1 (646) 536-7013
Joanna Zimmerman
The Ruth Group
Phone: +1 (646) 536-7006
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.11.2015 - 15:15 Uhr
Sprache: Deutsch
News-ID 1396612
Anzahl Zeichen: 2555
contact information:
Contact person:
Town:
PORT HUENEME, CA
Phone:
Kategorie:
Healthcare
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 122 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Stellar Biotechnologies Announces Approval of NASDAQ Uplisting
"
steht unter der journalistisch-redaktionellen Verantwortung von
Stellar Biotechnologies, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
